Search research articles
Contact Us
Filters
Showing results (121-130 of 128) with videos related to
Page
of 13
Sort By:
You have reached the last page of results.
This site can display upto 128 results.
The Pediatric Infectious Disease Journal
|
May 25, 2012
Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age
Mark M Blatter, Nicola P Klein, Julie S Shepard, et al.
Pediatrics
|
August 3, 2001
Growth and development in term infants fed long-chain polyunsaturated fatty acids: a double-masked, randomized, parallel, prospective, multivariate study
N Auestad, R Halter, R T Hall, et al.
Lancet (London, England)
|
November 16, 2004
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
Diane M Harper, Eduardo L Franco, Cosette Wheeler, et al.
The Journal of Infectious Diseases
|
August 18, 2001
Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants
M S Lee, D P Greenberg, S H Yeh, et al.
The Journal of Infectious Diseases
|
March 5, 2005
A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy
David P Greenberg, Robert E Walker, Min-Shi Lee, et al.
The Journal of Infectious Diseases
|
November 24, 1999
Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine
S Frey, R Dagan, Y Ashur, et al.
Vaccine
|
July 16, 2013
Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial
, R R Abu-Elyazeed, T Heineman, et al.
Lancet (London, England)
|
December 8, 2009
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years
, B Romanowski, P Colares de Borba, et al.
Page
of 13
Search research articles
Search
Showing results (121-130 of 128) with videos related to
Sort By:
Page
of 13
You have reached the last page of results.
This site can display upto 128 results.
The Pediatric Infectious Disease Journal
|
May 25, 2012
Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age
Mark M Blatter, Nicola P Klein, Julie S Shepard, et al.
Pediatrics
|
August 3, 2001
Growth and development in term infants fed long-chain polyunsaturated fatty acids: a double-masked, randomized, parallel, prospective, multivariate study
N Auestad, R Halter, R T Hall, et al.
Lancet (London, England)
|
November 16, 2004
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
Diane M Harper, Eduardo L Franco, Cosette Wheeler, et al.
The Journal of Infectious Diseases
|
August 18, 2001
Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants
M S Lee, D P Greenberg, S H Yeh, et al.
The Journal of Infectious Diseases
|
March 5, 2005
A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy
David P Greenberg, Robert E Walker, Min-Shi Lee, et al.
The Journal of Infectious Diseases
|
November 24, 1999
Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine
S Frey, R Dagan, Y Ashur, et al.
Vaccine
|
July 16, 2013
Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial
, R R Abu-Elyazeed, T Heineman, et al.
Lancet (London, England)
|
December 8, 2009
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years
, B Romanowski, P Colares de Borba, et al.
Page
of 13